Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 2
2012 2
2013 1
2014 2
2015 4
2017 1
2018 1
2019 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

10 results
Results by year
Filters applied: . Clear all
Page 1
[Chronic lymphocytic leukemia].
Jacque N, Leblond V. Jacque N, et al. Presse Med. 2019 Jul-Aug;48(7-8 Pt 1):807-815. doi: 10.1016/j.lpm.2019.07.019. Epub 2019 Aug 22. Presse Med. 2019. PMID: 31447332 Review. French.
Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition.
Jacque N, Ronchetti AM, Larrue C, Meunier G, Birsen R, Willems L, Saland E, Decroocq J, Maciel TT, Lambert M, Poulain L, Hospital MA, Sujobert P, Joseph L, Chapuis N, Lacombe C, Moura IC, Demo S, Sarry JE, Recher C, Mayeux P, Tamburini J, Bouscary D. Jacque N, et al. Blood. 2015 Sep 10;126(11):1346-56. doi: 10.1182/blood-2015-01-621870. Epub 2015 Jul 17. Blood. 2015. PMID: 26186940 Free PMC article.
Targeting glutamine uptake in AML.
Jacque N, Bouscary D. Jacque N, et al. Oncoscience. 2014 Jan 10;1(1):1-2. doi: 10.18632/oncoscience.1. eCollection 2014. Oncoscience. 2014. PMID: 25593985 Free PMC article. No abstract available.
Co-activation of AMPK and mTORC1 Induces Cytotoxicity in Acute Myeloid Leukemia.
Sujobert P, Poulain L, Paubelle E, Zylbersztejn F, Grenier A, Lambert M, Townsend EC, Brusq JM, Nicodeme E, Decrooqc J, Nepstad I, Green AS, Mondesir J, Hospital MA, Jacque N, Christodoulou A, Desouza TA, Hermine O, Foretz M, Viollet B, Lacombe C, Mayeux P, Weinstock DM, Moura IC, Bouscary D, Tamburini J. Sujobert P, et al. Among authors: jacque n. Cell Rep. 2015 Jun 9;11(9):1446-57. doi: 10.1016/j.celrep.2015.04.063. Epub 2015 May 21. Cell Rep. 2015. PMID: 26004183 Free article.
RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemia.
Hospital MA, Jacquel A, Mazed F, Saland E, Larrue C, Mondesir J, Birsen R, Green AS, Lambert M, Sujobert P, Gautier EF, Salnot V, Le Gall M, Decroocq J, Poulain L, Jacque N, Fontenay M, Kosmider O, Récher C, Auberger P, Mayeux P, Bouscary D, Sarry JE, Tamburini J. Hospital MA, et al. Among authors: jacque n. Leukemia. 2018 Mar;32(3):597-605. doi: 10.1038/leu.2017.284. Epub 2017 Sep 15. Leukemia. 2018. PMID: 28914261
Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia.
Green AS, Maciel TT, Hospital MA, Yin C, Mazed F, Townsend EC, Pilorge S, Lambert M, Paubelle E, Jacquel A, Zylbersztejn F, Decroocq J, Poulain L, Sujobert P, Jacque N, Adam K, So JC, Kosmider O, Auberger P, Hermine O, Weinstock DM, Lacombe C, Mayeux P, Vanasse GJ, Leung AY, Moura IC, Bouscary D, Tamburini J. Green AS, et al. Among authors: jacque n. Sci Adv. 2015 Sep 18;1(8):e1500221. doi: 10.1126/sciadv.1500221. eCollection 2015 Sep. Sci Adv. 2015. PMID: 26601252 Free PMC article.
Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia.
Willems L, Jacque N, Jacquel A, Neveux N, Maciel TT, Lambert M, Schmitt A, Poulain L, Green AS, Uzunov M, Kosmider O, Radford-Weiss I, Moura IC, Auberger P, Ifrah N, Bardet V, Chapuis N, Lacombe C, Mayeux P, Tamburini J, Bouscary D. Willems L, et al. Among authors: jacque n. Blood. 2013 Nov 14;122(20):3521-32. doi: 10.1182/blood-2013-03-493163. Epub 2013 Sep 6. Blood. 2013. PMID: 24014241 Free PMC article.
The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia.
Willems L, Chapuis N, Puissant A, Maciel TT, Green AS, Jacque N, Vignon C, Park S, Guichard S, Herault O, Fricot A, Hermine O, Moura IC, Auberger P, Ifrah N, Dreyfus F, Bonnet D, Lacombe C, Mayeux P, Bouscary D, Tamburini J. Willems L, et al. Among authors: jacque n. Leukemia. 2012 Jun;26(6):1195-202. doi: 10.1038/leu.2011.339. Epub 2011 Dec 6. Leukemia. 2012. PMID: 22143671
The eukaryotic initiating factor 4E protein is overexpressed, but its level has no prognostic impact in acute myeloid leukaemia.
Green AS, Grabar S, Tulliez M, Park S, Al-Nawakil C, Chapuis N, Jacque N, Willems L, Azar N, Ifrah N, Dreyfus F, Lacombe C, Mayeux P, Bouscary D, Tamburini J. Green AS, et al. Among authors: jacque n. Br J Haematol. 2012 Feb;156(4):547-50. doi: 10.1111/j.1365-2141.2011.08891.x. Epub 2011 Oct 14. Br J Haematol. 2012. PMID: 21995271 No abstract available.